Press Releases

Uncategorized

EASTGATE BIOTECH ENGAGES DISTRIBUTION COMPANY FOR ITS NUTRACEUTICAL PRODUCTS FOR CANADIAN MARKET

SALT LAKE CITY and TORONTO,  February 23, 2015 (PRNewswire/-) EastGate Biotech Corp. (OTCBB: EBTI), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules engages Preferred Nutrition (www.pno.ca) to distribute the company’s nutraceutical and natural consumer products across Canada.

Preferred Nutrition Inc. is a Canadian premier distribution company founded in 2002.  It primarily distributes to approximately 1,200 health food stores across Canada.  It represents 5 top product lines for a total of 78 products in the vitamin and supplement category.

Preferred Nutrition will initially start marketing E-drops which is a natural and herbal alternative that assists to rid the body of UTI infections painlessly and effectively without side effects of synthetic drugs.  Preferred Nutrition is also reviewing the marketing of other EastGate products, such as Vitamin D3 drops, Glucora, etc.

Information on EastGate’s natural product line can be found at www.nano-essentials.com   Previously, the company announced a distributor for its nutraceutical product line including E-drops in the United States under its own private label.

“We are pleased to have established a distribution relationship with Preferred Nutrition Inc. as it validates the marketplace’s demand for new and innovative products such as those delivered through EastGate’s proprietary sub-micron self-nanoemulsifying platform technology” says Anna Gluskin , EastGate’s CEO.  “E-drops, which is the first product that will be launched by Preferred Nutrition, is a unique product in its classification to aid in the natural elimination of UTI infections and the company’s distribution network will provide increased visibility to consumers in the growing natural product marketplace.”, continues Gluskin.

E-Drops Preferred Nutrition

Cautionary statement on forward-looking information

All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute “forward-looking information” or “forward-looking statements” within the meaning of certain securities laws, including the provisions for “safe harbour” under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.

The words “anticipates”, “plans”, “expects”, “indicate”, “intend”, “scheduled”, “estimates”, “forecasts”, “focus”, “guidance”, “initiative”, “model”, “methodology”, “outlook”, “potential”, “projected”, “pursue”, “strategy”, “study”, “targets”, or “believes”, or variations of or similar such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, or “should”, “might”, or “way forward”, “will be taken”, “will occur” or “will be achieved” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this release, include those identified from time to time in the reports filed by EastGate with the SEC, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:  Rose Perri 1-647-692-0652
Email:  information@eastgatepharmaceuticals.com
Website: www.EastGateBiotech.com

Leave a Reply

Your email address will not be published.

Sidebar